Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALYCANTE phase 2 study of axi-cel as second-line therapy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma patients ineligible for autologous stem cell transplantation
2024-513659-34-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Feb 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 2 more, sponsored by LYSARC. Primary endpoint: Complete metabolic response at 3 months. Planned start Feb 2021; status: authorised.
02
Drugs
axicabtagene ciloleucel
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2024-513659-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513659-34-00.